SymBio Pharmaceuticals (Japan) a commercial-stage pharmaceutical company focused on non-Hodgkin’s lymphoma, multiple myeloma and other hematological indications, closed a $24M Series E financing. Participants include Cephalon, Nippon Venture Capital, SMBC Venture Capital, MBL Venture Capital and JAFCO.